The ADAURA trial was an international, randomized, phase 3 study assessing the role of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, in completely resected, EGFR-mutated, stage IB to IIIA NSCLC (as per the 7th edition of the AJCC staging system) of non-squamous-cell histology, with or without administration of standard adjuvant chemotherapy (10). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.